GNPX 2017 Annual Report

42 Whether or not we obtain FDA approval for a product, we must obtain the required approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application equivalent to an IND prior to the commencement of human clinical trials. In the European Union, for example, a clinical trial authorization, or CTA, must be submitted to each countrys national health authority and an independent ethics committee, much like the FDA and the IRB, respectively. Once the CTA is approved in accordance with a countrys requirements, clinical trials may start. The requirements and process governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary from country to country. In all cases, the clinical trials are to be conducted in accordance with GCP, applicable regulatory requirements, and the ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension, or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution in those countries. Employees As of April 6,2018, we had four full-time employees and one part-time employee, and accordingly, a high percentage of the work performed for our development projects is outsourced to qualified independent contractors. Geographic Information During 2017 and 2016 all of our long-lived assets were located in the United States of America. Corporate Information We were incorporated in Delaware in April 2009. Our principal executive offices are located at 100 Congress Avenue, Suite 2000, Austin, TX 78701, and our telephone number is (512) 370-4081. Our corporate website address is www.genprex.com . Information contained on, or that can be accessed through, our website or social medial sites does not constitute part of this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual references only. This Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available (free of charge) on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. We have proprietary rights to a number of trademarks, including Oncoprex, that are used in this Annual Report on Form 10- K. Solely for convenience, the trademarks and trade names in this Annual Report on From 10-K are generally referred to without the ® and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. All other trademarks, trade names and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. We qualify as an emerging growth company as the term is used in The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and therefore, we may take advantage of certain exemptions from various public company reporting requirements, including: • a requirement to only have two years of audited financial statements and only two years of related selected financial data and managements discussion and analysis; • exemption from the auditor attestation requirement on the effectiveness of our internal controls over financial reporting; • reduced disclosure obligations regarding executive compensation; and • exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments.